A Phase 3 interventional study of Pelabresib and Ruxolitinib in Myelofibrosis, Primary Myelofibrosis and Post-polycythemia Vera Myelofibrosis, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 156 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-17.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Primary Myelofibrosis by Novartis — 1 open to participants now, 4 under way, 2 of them phase 3. Primary Myelofibrosis · Novartis.
Among the 24 studies in Primary Myelofibrosis by Novartis, this one is the 4th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 3, and was the 19th registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.
Browse Primary Myelofibrosis studies →1 of the 24 studies in Primary Myelofibrosis by Novartis is open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 21 more countries
Ages 18+
By country, each count listing its studies:
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 7 · Phase 4 2
First in 2001; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 430 is above the median of 43 across 491 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 51 across the 21 interventional studies, 684 across the 2 observational. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 24 studies in Primary Myelofibrosis by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pelabresib monohydrate tablets + ruxolitinib phosphate tablets
Drug: Pelabresib · Drug: Ruxolitinib
Matching placebo tablets + ruxolitinib phosphate tablets
Drug: Ruxolitinib · Drug: Placebo
Double-blind treatment (pelabresib or matching placebo) will be administered daily for 14 consecutive days followed by a 7-day break, which is considered 1 cycle of treatment (1 cycle = 21 days). Pelabresib is a small molecule inhibitor of BET proteins with a novel mechanism of action and potential for disease-modifying effects in MF.
Ruxolitinib is a JAK inhibitor and a current, approved treatment option for MF.
Placebo tablets are designed to match pelabresib tablets. Each placebo tablet contains no active pharmaceutical ingredient and is visibly identical to experimental drug in size, shape, and packaging. Placebo dosing follows the same dosing conventions as pelabresib.
Number of Participants With Splenic Response by Central Radiology Reads at Week 24
Splenic response was characterized by a reduction of at least 35% in spleen volume from baseline (SVR35), as determined by magnetic resonance imaging (MRI) or computerized tomography (CT), and evaluated through a blinded central radiology review at Week 24.
Time frame: Week 24
Key Secondary: Absolute Change From Baseline in Total Symptom Score (TSS) at Week 24
The Total Symptom Score (TSS) at Week 24, compared to baseline, was measured using the Myelofibrosis Symptom Assessment Form v4.0. This score represented the sum of seven individual symptom items, each rated on a 0-10 scale, resulting in a possible total daily score ranging from 0 to 70. A higher TSS reflected a greater disease burden and therefore a worse outcome. The baseline TSS was calculated as the average of non-missing daily total symptom scores over the seven-day period preceding the day of randomization. The TSS for each treatment week was determined as the average of non-missing daily total symptom scores for that week. However, if fewer than four daily scores were available for a given week, the weekly TSS was considered missing.
Time frame: Baseline, Week 24
Key Secondary: Number of Participants With TSS50 Response at Week 24
The probability of a TSS response at Week 24 was estimated by calculating the TSS response rate, defined as the percentage of patients who achieved a TSS50 response at Week 24 in each of the two treatment groups. The Total Symptom Score (TSS) response was defined as a ≥50% reduction from baseline in TSS, as measured by the Myelofibrosis Symptom Assessment Form v4.0.
Time frame: Week 24
Percent Change From Baseline in Total Symptom Score (TSS) at Week 24
Percent Change From Baseline in Total Symptom Score (TSS) at Week 24 measured the change in a patient's symptoms after 24 weeks of treatment, relative to baseline. A negative value indicates symptom improvement, and a reduction of ≥50% is typically considered a meaningful clinical response.
Time frame: Baseline, Week 24
Number of Participants With Improvement From Baseline in Bone Marrow Fibrosis of at Least 1 Grade at Week 24
Improvement in bone marrow fibrosis by at least 1 grade, as assessed by central read compared to baseline, was analyzed by treatment group and overall. The improvement in bone marrow fibrosis grade was defined as a decrease by at least 1 grade in bone marrow fibrosis grade when compared to baseline, where a grade of MF-3 was the most severe, and MF-0 was the least severe.
Time frame: Baseline, Week 24
Number of Participants With Splenic Response by Central Radiology Reads at Week 48
Splenic response is characterized by a reduction of at least 35% in spleen volume from baseline (SVR35), as determined by magnetic resonance imaging (MRI) or computerized tomography (CT), and evaluated through a blinded central radiology review at Week 48.
Time frame: Week 48
Number of Participants With TSS50 Response at Week 48
The probability of a TSS response at Week 48 is estimated by calculating the TSS response rate, defined as the percentage of patients who achieve a TSS50 response at Week 48 in each of the two treatment groups. The Total Symptom Score (TSS) response is defined as a ≥50% reduction from baseline in TSS, as measured by the Myelofibrosis Symptom Assessment Form v4.0.
Time frame: Week 48
Absolute Change From Baseline in Total Symptom Score (TSS) at Week 48
The Total Symptom Score (TSS) at Week 48, compared to baseline, is measured using the Myelofibrosis Symptom Assessment Form v4.0. This score represents the sum of seven individual symptom items, each rated on a 0-10 scale, resulting in a possible total daily score ranging from 0 to 70. A higher TSS reflects a greater disease burden and therefore a worse outcome. The baseline TSS is calculated as the average of non-missing daily total symptom scores over the seven-day period preceding the day of randomization. The TSS for each treatment week is determined as the average of non-missing daily total symptom scores for that week. However, if fewer than four daily scores are available for a given week, the weekly TSS is considered missing.
Time frame: Baseline, Week 48
Rate of Red Blood Cell (RBC) Transfusion Over First 24 Weeks of Treatment
The rate of RBC transfusions was defined as the average number of RBC units transfused per patient month (4 weeks) during the first 24 weeks of treatment. The average number of RBC units per patient-month was calculated by dividing the total (ie, for all patients) number of RBC units in the whole exposure time by the sum of patient-months.
Time frame: Week 24
Number of Participants Who Transitioned From Red Blood Cell (RBC) Transfusion Dependence to Transfusion Independence
Transfusion dependence (TD) was defined as having received ≥6 units of RBCs during the 12-week baseline period prior to dosing and Transfusion independence (TI) was defined as the absence of RBC transfusions during any continuous 12-week period of the double-blind treatment phase. The conversion from TD to TI was evaluated and defined as the proportion of patients who transitioned from transfusion dependence to transfusion independence. Patients who remained in the double-blind treatment period and had not received any RBC transfusions during the most recent 12 weeks were considered responders. Patients who discontinued from the double-blind treatment before Week 12 were classified as non-responders.
Time frame: From 12-week baseline period prior to dosing to any 12-week period post baseline, up to 24 weeks
Category Change From Baseline of Patient Global Impression of Change (PGIC) at Week 24
The Patient Global Impression of Change (PGIC) was a single-item measure of the patient's perceived change in MF symptoms since starting treatment. Patients responded to: "Since beginning this study treatment, your myelofibrosis symptoms were: (1) Very much improved, (2) Much improved, (3) Minimally improved, (4) No change, (5) Minimally worse, (6) Much worse, (7) Very much worse."
Time frame: Baseline, Week 24
Progression-Free Survival (PFS)
Progression-Free Survival (PFS), defined as the time from randomization until documented progression, or until death from any cause for patients without documented progression
Time frame: Through study completion, an average of 6 years
Overall Survival (OS)
OS, defined as the time from randomization until death from any cause
Time frame: Through study completion, an average of 6 years
Proportion of Patients With Transformation to Blast Phase (AML)
Patients are categorized as having transformed to Acute Myelogenous Leukemia (AML) when the peripheral blood blast percentage increases to ≥20% and this elevation persists for at least two weeks, or when leukemic transformation is confirmed through disease status assessment.
Time frame: Through study completion, an average of 6 years
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
A treatment-emergent adverse event (TEAE) for the double-blind treatment period is defined as an AE that has a start date on or after the first dose of the pelabresib/placebo and before 30 days after the last dose of pelabresib/placebo or before the start of alternative (off-study) treatment for MF, whichever occurs first. If the AE has a start date before the date of first dose but increases in severity after first dose and before 30 days post last dose will be considered a TEAE as well. An AE that occurs after the administration of the first dose of open-label pelabresib treatment will be considered treatment-emergent for the crossover treatment period. However, a TEAE for the crossover treatment period that occurs within 30 days after the last dose of pelabresib/placebo will be considered treatment emergent for the double-blind treatment period as well.
Time frame: Through study completion, an average of 6 years
Pharmacokinetic (PK) Parameters for Pelabresib: Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC0-t)
Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. AUC0-t will be listed and summarized using descriptive statistics.
Time frame: Cycle 1 Day 1, Cycle 1 Day 14 and Cycle 9 Day 1: Predose, 30 minutes to 1 hour post-dose, 3 to 4.5 hours post-dose. Cycle 3 and Cycle 7 Day 1: Predose, 5 minutes post ECG assessment. 1 Cycle = 21 days
Pharmacokinetic (PK) Parameters for Pelabresib: Time to Reach Maximum (Peak) Plasma Concentration Following Drug Administration (Tmax)
Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. AUC0-t will be listed and summarized using descriptive statistics. Tmax will be listed and summarized using descriptive statistics.
Time frame: Cycle 1 Day 1, Cycle 1 Day 14 and Cycle 9 Day 1: Predose, 30 minutes to 1 hour post-dose, 3 to 4.5 hours post-dose. Cycle 3 and Cycle 7 Day 1: Predose, 5 minutes post ECG assessment. 1 Cycle = 21 days
Pharmacokinetic (PK) Parameters for Pelabresib: Maximum (Peak) Plasma Drug Concentration (Cmax)
Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. AUC0-t will be listed and summarized using descriptive statistics. Cmax will be listed and summarized using descriptive statistics.
Time frame: Cycle 1 Day 1, Cycle 1 Day 14 and Cycle 9 Day 1: Predose, 30 minutes to 1 hour post-dose, 3 to 4.5 hours post-dose. Cycle 3 and Cycle 7 Day 1: Predose, 5 minutes post ECG assessment. 1 Cycle = 21 days
Pharmacokinetic (PK) Parameters for Pelabresib: Effective Half-Life (T1/2)
Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. T1/2 will be listed and summarized using descriptive statistics.
Time frame: Cycle 1 Day 1, Cycle 1 Day 14 and Cycle 9 Day 1: Predose, 30 minutes to 1 hour post-dose, 3 to 4.5 hours post-dose. Cycle 3 and Cycle 7 Day 1: Predose, 5 minutes post ECG assessment. 1 Cycle = 21 days
Pharmacokinetic (PK) Parameters for Pelabresib: Apparent Volume of Distribution After Non-intravenous Administration (Vd/F)
Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. Vd/F will be listed and summarized using descriptive statistics.
Time frame: Cycle 1 Day 1, Cycle 1 Day 14 and Cycle 9 Day 1: Predose, 30 minutes to 1 hour post-dose, 3 to 4.5 hours post-dose. Cycle 3 and Cycle 7 Day 1: Predose, 5 minutes post ECG assessment. 1 Cycle = 21 days
Pharmacokinetic (PK) Parameters for Pelabresib: Apparent Total Clearance of the Drug From Plasma After Oral Administration (CL/F)
Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. CL/F will be listed and summarized using descriptive statistics.
Time frame: Cycle 1 Day 1, Cycle 1 Day 14 and Cycle 9 Day 1: Predose, 30 minutes to 1 hour post-dose, 3 to 4.5 hours post-dose. Cycle 3 and Cycle 7 Day 1: Predose, 5 minutes post ECG assessment. 1 Cycle = 21 days
Ruxolitinib Plasma Concentrations in the Presence or Absence of Pelabresib
Blood samples (approximately 4 mL each) will be collected at the time points specified in the Schedule of Assessments (SOA) to determine plasma concentrations of Ruxolitinib plasma concentrations in the presence or absence of Pelabresib
Time frame: Cycle 1 Day 1, Cycle 1 Day 14 and Cycle 9 Day 1: Predose, 30 minutes to 1 hour post-dose, 3 to 4.5 hours post-dose. Cycle 3 and Cycle 7 Day 1: Predose, 5 minutes post ECG assessment. 1 Cycle = 21 days
Duration of the Splenic Response
Duration of splenic response, defined as the time from onset of splenic response until the time at which the patient has a \<35% decrease from baseline in spleen volume and a \>25% increase from nadir, as confirmed by the central review) or death, whichever comes first
Time frame: Through study completion, an average of 6 years
Number of Participants With Modified Total Symptom Score (mTSS) Response at Week 24
The modified TSS (mTSS) was defined as TSS without the fatigue sub-domain and with a total scale of 60 points versus 70 points for TSS. Patients were classified as responders if the percentage of change from baseline in mTSS was ≤ -50% at Week 24.
Time frame: Week 24
Duration of the TSS50 Response
Duration of TSS response, defined as the time from onset of TSS50 response until the time at which the patient has a \<50% reduction in TSS from baseline and an increase of ≥25% from nadir
Time frame: Through study completion, an average of 6 years
A total of 135 centers enrolled patients in the study in Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Malaysia, Netherlands, Poland, South Korea, Spain, Taiwan, Thailand, Turkey, United Kingdom, and United States.
| Milestone | Pelabresib + Ruxolitinib (Experimental Arm) | Placebo + Ruxolitinib (Control Arm) |
|---|---|---|
| Started | 214 | 216 |
| Modified intent-to-treat (mitt) analysis set | 212 | 214 |
| Safety analysis set | 212 | 214 |
| Per-protocol set (pp set) | 196 | 194 |
| Pharmacokinetic (pk) analysis set | 212 | 211 |
| Biomarker analysis set | 212 | 214 |
| Ongoing on double-blind treatment | 154 | 160 |
| Discontinued double-blind treatment | 58 | 54 |
| On pfs/os follow-up | 22 | 30 |
| Completed | 176 | 190 |
| Not completed | 38 | 26 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Death | 10 | 11 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Physician decision | 3 | 3 |
| Withdrew: Patient non-compliance/protocol violation(s) | 2 | 0 |
| Withdrew: Withdrawal of consent for follow-up | 21 | 9 |
| Withdrew: Patient became eligible for transplant | 0 | 1 |
Splenic response was characterized by a reduction of at least 35% in spleen volume from baseline (SVR35), as determined by magnetic resonance imaging (MRI) or computerized tomography (CT), and evaluated through a blinded central radiology review at Week 24.
| Participants | Pelabresib + Ruxolitinib (Experimental Arm) | Placebo + Ruxolitinib (Control Arm) |
|---|---|---|
| Number of Participants With Splenic Response by Central Radiology Reads at Week 24 | 141 | 76 |
The Total Symptom Score (TSS) at Week 24, compared to baseline, was measured using the Myelofibrosis Symptom Assessment Form v4.0. This score represented the sum of seven individual symptom items, each rated on a 0-10 scale, resulting in a possible total daily score ranging from 0 to 70. A higher TSS reflected a greater disease burden and therefore a worse outcome. The baseline TSS was calculated as the average of non-missing daily total symptom scores over the seven-day period preceding the day of randomization. The TSS for each treatment week was determined as the average of non-missing daily total symptom scores for that week. However, if fewer than four daily scores were available for a given week, the weekly TSS was considered missing.
| score on a scale | Pelabresib + Ruxolitinib (Experimental Arm) | Placebo + Ruxolitinib (Control Arm) |
|---|---|---|
| Key Secondary: Absolute Change From Baseline in Total Symptom Score (TSS) at Week 24 | -15.99 ± 1.028 | -14.05 ± 0.986 |
The probability of a TSS response at Week 24 was estimated by calculating the TSS response rate, defined as the percentage of patients who achieved a TSS50 response at Week 24 in each of the two treatment groups. The Total Symptom Score (TSS) response was defined as a ≥50% reduction from baseline in TSS, as measured by the Myelofibrosis Symptom Assessment Form v4.0.
| Participants | Pelabresib + Ruxolitinib (Experimental Arm) | Placebo + Ruxolitinib (Control Arm) |
|---|---|---|
| Key Secondary: Number of Participants With TSS50 Response at Week 24 | 112 | 100 |
Percent Change From Baseline in Total Symptom Score (TSS) at Week 24 measured the change in a patient's symptoms after 24 weeks of treatment, relative to baseline. A negative value indicates symptom improvement, and a reduction of ≥50% is typically considered a meaningful clinical response.
| Percent change from baseline to Week 24 | Pelabresib + Ruxolitinib (Experimental Arm) | Placebo + Ruxolitinib (Control Arm) |
|---|---|---|
| Percent Change From Baseline in Total Symptom Score (TSS) at Week 24 | -50.3 (-56.6 to -44.0) | -45.9 (-51.8 to -40.0) |
Improvement in bone marrow fibrosis by at least 1 grade, as assessed by central read compared to baseline, was analyzed by treatment group and overall. The improvement in bone marrow fibrosis grade was defined as a decrease by at least 1 grade in bone marrow fibrosis grade when compared to baseline, where a grade of MF-3 was the most severe, and MF-0 was the least severe.
| Participants | Pelabresib + Ruxolitinib (Experimental Arm) | Placebo + Ruxolitinib (Control Arm) |
|---|---|---|
| Number of Participants With Improvement From Baseline in Bone Marrow Fibrosis of at Least 1 Grade at Week 24 | 36 | 21 |
Splenic response is characterized by a reduction of at least 35% in spleen volume from baseline (SVR35), as determined by magnetic resonance imaging (MRI) or computerized tomography (CT), and evaluated through a blinded central radiology review at Week 48.
Results for this outcome have not been posted.
The probability of a TSS response at Week 48 is estimated by calculating the TSS response rate, defined as the percentage of patients who achieve a TSS50 response at Week 48 in each of the two treatment groups. The Total Symptom Score (TSS) response is defined as a ≥50% reduction from baseline in TSS, as measured by the Myelofibrosis Symptom Assessment Form v4.0.
Results for this outcome have not been posted.
The Total Symptom Score (TSS) at Week 48, compared to baseline, is measured using the Myelofibrosis Symptom Assessment Form v4.0. This score represents the sum of seven individual symptom items, each rated on a 0-10 scale, resulting in a possible total daily score ranging from 0 to 70. A higher TSS reflects a greater disease burden and therefore a worse outcome. The baseline TSS is calculated as the average of non-missing daily total symptom scores over the seven-day period preceding the day of randomization. The TSS for each treatment week is determined as the average of non-missing daily total symptom scores for that week. However, if fewer than four daily scores are available for a given week, the weekly TSS is considered missing.
Results for this outcome have not been posted.
The rate of RBC transfusions was defined as the average number of RBC units transfused per patient month (4 weeks) during the first 24 weeks of treatment. The average number of RBC units per patient-month was calculated by dividing the total (ie, for all patients) number of RBC units in the whole exposure time by the sum of patient-months.
| RBC units transfused/patient-months | Pelabresib + Ruxolitinib (Experimental Arm) | Placebo + Ruxolitinib (Control Arm) |
|---|---|---|
| Rate of Red Blood Cell (RBC) Transfusion Over First 24 Weeks of Treatment | 1.359 (0.982 to 1.736) | 1.014 (0.840 to 1.188) |
Transfusion dependence (TD) was defined as having received ≥6 units of RBCs during the 12-week baseline period prior to dosing and Transfusion independence (TI) was defined as the absence of RBC transfusions during any continuous 12-week period of the double-blind treatment phase. The conversion from TD to TI was evaluated and defined as the proportion of patients who transitioned from transfusion dependence to transfusion independence. Patients who remained in the double-blind treatment period and had not received any RBC transfusions during the most recent 12 weeks were considered responders. Patients who discontinued from the double-blind treatment before Week 12 were classified as non-responders.
| Participants | Pelabresib + Ruxolitinib (Experimental Arm) | Placebo + Ruxolitinib (Control Arm) |
|---|---|---|
| Number of Participants Who Transitioned From Red Blood Cell (RBC) Transfusion Dependence to Transfusion Independence | 0 | 0 |
The Patient Global Impression of Change (PGIC) was a single-item measure of the patient's perceived change in MF symptoms since starting treatment. Patients responded to: "Since beginning this study treatment, your myelofibrosis symptoms were: (1) Very much improved, (2) Much improved, (3) Minimally improved, (4) No change, (5) Minimally worse, (6) Much worse, (7) Very much worse."
| Participants | Pelabresib + Ruxolitinib (Experimental Arm) | Placebo + Ruxolitinib (Control Arm) |
|---|---|---|
| Very much improved | 24 | 26 |
| Much improved | 63 | 62 |
| Minimally improved | 63 | 79 |
| No change | 14 | 13 |
| Minimally worse | 7 | 14 |
| Much worse | 5 | 0 |
| Very much worse | 1 | 0 |
Progression-Free Survival (PFS), defined as the time from randomization until documented progression, or until death from any cause for patients without documented progression
Results for this outcome have not been posted.
OS, defined as the time from randomization until death from any cause
Results for this outcome have not been posted.
Patients are categorized as having transformed to Acute Myelogenous Leukemia (AML) when the peripheral blood blast percentage increases to ≥20% and this elevation persists for at least two weeks, or when leukemic transformation is confirmed through disease status assessment.
Results for this outcome have not been posted.
A treatment-emergent adverse event (TEAE) for the double-blind treatment period is defined as an AE that has a start date on or after the first dose of the pelabresib/placebo and before 30 days after the last dose of pelabresib/placebo or before the start of alternative (off-study) treatment for MF, whichever occurs first. If the AE has a start date before the date of first dose but increases in severity after first dose and before 30 days post last dose will be considered a TEAE as well. An AE that occurs after the administration of the first dose of open-label pelabresib treatment will be considered treatment-emergent for the crossover treatment period. However, a TEAE for the crossover treatment period that occurs within 30 days after the last dose of pelabresib/placebo will be considered treatment emergent for the double-blind treatment period as well.
Results for this outcome have not been posted.
Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. AUC0-t will be listed and summarized using descriptive statistics.
Results for this outcome have not been posted.
Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. AUC0-t will be listed and summarized using descriptive statistics. Tmax will be listed and summarized using descriptive statistics.
Results for this outcome have not been posted.
Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. AUC0-t will be listed and summarized using descriptive statistics. Cmax will be listed and summarized using descriptive statistics.
Results for this outcome have not been posted.
Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. T1/2 will be listed and summarized using descriptive statistics.
Results for this outcome have not been posted.
Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. Vd/F will be listed and summarized using descriptive statistics.
Results for this outcome have not been posted.
Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. CL/F will be listed and summarized using descriptive statistics.
Results for this outcome have not been posted.
Blood samples (approximately 4 mL each) will be collected at the time points specified in the Schedule of Assessments (SOA) to determine plasma concentrations of Ruxolitinib plasma concentrations in the presence or absence of Pelabresib
Results for this outcome have not been posted.
Duration of splenic response, defined as the time from onset of splenic response until the time at which the patient has a \<35% decrease from baseline in spleen volume and a \>25% increase from nadir, as confirmed by the central review) or death, whichever comes first
Results for this outcome have not been posted.
The modified TSS (mTSS) was defined as TSS without the fatigue sub-domain and with a total scale of 60 points versus 70 points for TSS. Patients were classified as responders if the percentage of change from baseline in mTSS was ≤ -50% at Week 24.
| Participants | Pelabresib + Ruxolitinib (Experimental Arm) | Placebo + Ruxolitinib (Control Arm) |
|---|---|---|
| Number of Participants With Modified Total Symptom Score (mTSS) Response at Week 24 | 120 | 104 |
Duration of TSS response, defined as the time from onset of TSS50 response until the time at which the patient has a \<50% reduction in TSS from baseline and an increase of ≥25% from nadir
Results for this outcome have not been posted.
Collected over Adverse Events (AEs) on-treatment period are collected from the first dose of pelabresib/placebo until 30 days after the last dose of pelabresib/placebo or the initiation of alternative (off-study) treatment for myelofibrosis (MF), whichever occurred first, up to the cut-off date for the interim analysis (31-Aug-2023), an average of 47 weeks. Deaths were collected from start of study up to the cut-off date for the interim analysis (31-Aug-2023), up to approximately of 28 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pelabresib + Ruxolitinib (On-Treatment) | 5/214 (2.3%) | 63/212 (29.7%) | 199/212 (93.9%) |
| Placebo + Ruxolitinib (On-Treatment) | 6/216 (2.8%) | 63/214 (29.4%) | 200/214 (93.5%) |
| Pelabresib + Ruxolitinib (Post-Treatment) | 7/209 (3.3%) | — | — |
| Placebo + Ruxolitinib (Post-Treatment) | 5/210 (2.4%) | — | — |
| Event | Pelabresib + Ruxolitinib (On-Treatment) | Placebo + Ruxolitinib (On-Treatment) | Pelabresib + Ruxolitinib (Post-Treatment) | Placebo + Ruxolitinib (Post-Treatment) |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 7/212 | 6/214 | — | — |
| AnaemiaBlood and lymphatic system disorders | 5/212 | 5/214 | — | — |
| Herpes zosterInfections and infestations | 4/212 | 0/214 | — | — |
| SepsisInfections and infestations | 3/212 | 2/214 | — | — |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/212 | 2/214 | — | — |
| Cardiac failureCardiac disorders | 0/212 | 3/214 | — | — |
| COVID-19Infections and infestations | 0/212 | 3/214 | — | — |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/212 | 3/214 | — | — |
| ArrhythmiaCardiac disorders | 2/212 | 0/214 | — | — |
| Cardiac arrestCardiac disorders | 2/212 | 0/214 | — | — |
| Event | Pelabresib + Ruxolitinib (On-Treatment) | Placebo + Ruxolitinib (On-Treatment) | Pelabresib + Ruxolitinib (Post-Treatment) | Placebo + Ruxolitinib (Post-Treatment) |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 90/212 | 116/214 | — | — |
| ThrombocytopeniaBlood and lymphatic system disorders | 68/212 | 50/214 | — | — |
| ConstipationGastrointestinal disorders | 39/212 | 52/214 | — | — |
| DiarrhoeaGastrointestinal disorders | 49/212 | 39/214 | — | — |
| Platelet count decreasedInvestigations | 44/212 | 34/214 | — | — |
| DysgeusiaNervous system disorders | 39/212 | 8/214 | — | — |
| FatigueGeneral disorders | 25/212 | 34/214 | — | — |
| NauseaGastrointestinal disorders | 30/212 | 32/214 | — | — |
| COVID-19Infections and infestations | 24/212 | 32/214 | — | — |
| AstheniaGeneral disorders | 25/212 | 30/214 | — | — |
Intent-to-Treat Population. All randomized patients. This is the primary population for all efficacy endpoints. All analyses using this population will be based on the treatment assigned by the Interactive Response Technology (IRT) system.
| Age, Categorical(Participants) | Pelabresib + Ruxolitinib (Experimental Arm) | Placebo + Ruxolitinib (Control Arm) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 94 | 92 | 186 |
| >=65 years | 120 | 124 | 244 |
| Age, Continuous(years) | Pelabresib + Ruxolitinib (Experimental Arm) | Placebo + Ruxolitinib (Control Arm) | Total |
|---|---|---|---|
| Mean | 64.5 ± 11.84 | 64.8 ± 11.08 | 64.7 ± 11.45 |
| Sex: Female, Male(Participants) | Pelabresib + Ruxolitinib (Experimental Arm) | Placebo + Ruxolitinib (Control Arm) | Total |
|---|---|---|---|
| Female | 85 | 94 | 179 |
| Male | 129 | 122 | 251 |
| Ethnicity (NIH/OMB)(Participants) | Pelabresib + Ruxolitinib (Experimental Arm) | Placebo + Ruxolitinib (Control Arm) | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 6 | 9 |
| Not Hispanic or Latino | 194 | 199 | 393 |
| Unknown or Not Reported | 17 | 11 | 28 |
| Race (NIH/OMB)(Participants) | Pelabresib + Ruxolitinib (Experimental Arm) | Placebo + Ruxolitinib (Control Arm) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 35 | 42 | 77 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 160 | 163 | 323 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 16 | 11 | 27 |
| Dynamic International Prognostic Scoring System (DIPSS) risk category(Participants) | Pelabresib + Ruxolitinib (Experimental Arm) | Placebo + Ruxolitinib (Control Arm) | Total |
|---|---|---|---|
| Intermediate-1 | 128 | 127 | 255 |
| Intermediate-2 | 75 | 74 | 149 |
| High | 11 | 15 | 26 |
| Platelet count(Participants) | Pelabresib + Ruxolitinib (Experimental Arm) | Placebo + Ruxolitinib (Control Arm) | Total |
|---|---|---|---|
| >200 × 10^9 cells/L | 154 | 157 | 311 |
| 100-200 × 10^9 cells/L | 59 | 57 | 116 |
| <100 × 10^9 cells/L | 1 | 2 | 3 |
| Hemoglobin(Participants) | Pelabresib + Ruxolitinib (Experimental Arm) | Placebo + Ruxolitinib (Control Arm) | Total |
|---|---|---|---|
| >10 g/dL | 144 | 140 | 284 |
| ≤10 g/dL | 70 | 76 | 146 |
3 further baseline measures are reported on the registry.
Showing the first 100 of 156 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Apr 2021 to primary completion in Aug 2023, 28 months.
Results were first posted in Oct 2024, 1 year 2 months after primary completion.
Of 22 phase 3 interventional studies under Primary Myelofibrosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 68. This study's 28 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CPI-0610